What Is Amniocentesis?

Amniocentesis is an invasive prenatal diagnostic procedure in which a sample of amniotic fluid is aspirated from the amniotic cavity surrounding the fetus. The fluid contains fetal cells, proteins, and biochemical markers that can be analyzed to identify chromosomal abnormalities, single-gene disorders, neural tube defects, and certain fetal infections. It is the most commonly performed invasive fetal diagnostic test and is typically carried out between 15 and 20 weeks of gestation, though it can be performed at any point after that window through delivery when clinical circumstances require. The procedure draws on genetics, ultrasonography, and obstetric medicine.

Amniocentesis became practical for chromosomal diagnosis in the 1960s following the development of techniques to culture and karyotype fetal cells. The introduction of real-time ultrasound guidance in the 1970s substantially improved safety by allowing the operator to visualize the needle tip, the fetus, and the placenta throughout the procedure. Modern amniocentesis reflects advances in both imaging resolution and genomic analysis, with whole-genome and targeted sequencing methods now supplementing classical karyotyping for higher-resolution chromosomal and genetic analysis.

Ultrasound-Guided Procedure

Under continuous real-time ultrasound visualization, the operator identifies a pocket of amniotic fluid that is free of fetal parts and away from the placenta. A 20- to 22-gauge spinal needle is advanced through the maternal abdominal wall and uterine wall into the amniotic cavity, and approximately 15 to 20 mL of amniotic fluid is withdrawn into a syringe. The first few milliliters are typically discarded or set aside to minimize the risk of maternal cell contamination, which could confound laboratory results. Ultrasound guidance reduces inadvertent fetal injury and allows immediate assessment of the fetal heart rate following needle withdrawal. The StatPearls clinical review of amniocentesis at NCBI Bookshelf provides a detailed procedural description, including needle gauge selection, fluid handling, and the influence of operator experience on complication rates.

Genetic and Chromosomal Analysis

Amniotic fluid cells, primarily fetal fibroblasts shed from the skin, gastrointestinal tract, and urinary tract, are cultured in the laboratory to obtain sufficient cell numbers for karyotyping, typically requiring one to two weeks. Standard karyotyping visualizes the complete set of chromosomes at a resolution that detects aneuploidies, including trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), and trisomy 13 (Patau syndrome), as well as larger chromosomal deletions and duplications. Chromosomal microarray analysis, which has largely supplemented or replaced standard karyotyping in many centers, detects copy number variants below the resolution of conventional cytogenetics and returns results in five to seven days without the need for cell culture. ACOG's guidance on prenatal genetic diagnostic tests describes the current clinical indications for amniocentesis and the relative roles of karyotyping, chromosomal microarray, and targeted mutation analysis. The amniotic fluid supernatant is analyzed separately for alpha-fetoprotein and acetylcholinesterase, markers of open neural tube defects such as spina bifida and anencephaly.

Risks and Limitations

The procedure carries a small risk of pregnancy loss, with contemporary data from experienced centers placing the procedure-attributable rate at approximately 0.11 percent. Amniotic fluid leakage occurs in one to two percent of cases and usually resolves spontaneously within a week. Infection risk is below 0.1 percent when standard antiseptic technique is observed. The procedure cannot detect all fetal abnormalities; structural anomalies visible on ultrasound, placental insufficiency, and many congenital malformations fall outside the scope of amniocentesis. Mayo Clinic's summary of amniocentesis indications and risks outlines the counseling framework used to help patients weigh diagnostic benefit against procedural risk.

Applications

Amniocentesis has applications across several areas of reproductive medicine and genetic diagnosis, including:

• Chromosomal aneuploidies: detection of trisomy 21, 18, and 13 and sex chromosome disorders
• Monogenic diseases: diagnosis of cystic fibrosis, sickle cell disease, and Tay-Sachs disease
• Neural tube defects: alpha-fetoprotein quantification for spina bifida and anencephaly
• Fetal infection: testing for cytomegalovirus, toxoplasmosis, and other intrauterine pathogens
• Fetal lung maturity: lecithin-to-sphingomyelin ratio assessment in late-pregnancy management